Table 1.
Clinical features of sarcoidosis subjects.
| # | Organs affected by sarcoidosis | Thoracic LAN | Years btw diagnosis and enrollment | Treatment-naïve at enrollment? Type of treatment and indication |
Type of treatment and indication at 1 year of follow-up |
|---|---|---|---|---|---|
| 1 | Lungs (51-75%), heart, extra-thoracic LN | No | 0.15 | No Tx | Steroids |
| 2 | Lungs (51-75%) | No imaging data | 0.44 | No Tx | No follow-up data |
| 3 | Lungs (51-75%), heart, spleen | Yes | 1.29 | Steroids | IFX, refractory disease |
| 4 | Lungs (51-75%), heart, liver | No | 3.64 | Steroids + MTX | No Tx |
| 5 | Lungs (51-75%) | Yes | 0.09 | No Tx | No Tx |
| 6 | Lungs (6-25%), skin | No | 1.95 | Steroids | No Tx |
| 7 | Lungs (26-50%) | Yes | 0.94 | No Tx | No Tx |
| 8 | Lungs (51-75%), heart | Yes | 10.96 | Steroids + MTX | No Tx |
| 9 | Lungs (76-100%) | No | 0.59 | No Tx | No Tx |
| 10 | Lungs (26-50%) | Yes | 0.07 | No Tx, but Abatacept (CTLA4–Ig) for RA | No Tx |
| 11 | Lungs (26-50%) | Yes | 0.32 | No Tx | Steroids + IFX |
| 12 | Lungs (51-75%) | No | 1.76 | MTX 25 mg weekly | No Tx |
| 13 | Lungs (<5%) | Yes | 1.75 | No Tx | No Tx |
| 14 | Lungs (26-50%), spleen | Yes | 3.02 | No Tx | No Tx |
| 15 | Lungs (6-25%), eyes, CNS, spleen | Yes | 0.07 | No Tx | Steroids |
| 16 | Lungs (<5%) | Yes | 0.00 | No Tx | No follow-up data |
| 17 | Lungs (6-25%), spleen, skin | No | 0.01 | No Tx | No Tx |
| 18 | Lungs (<5%), eyes, skin, extra-thoracic LN | Yes | 5.76 | Acthar Gel | Steroids |
| 19 | Lungs (51-75%) | Yes | 0.00 | No Tx | Steroids |
| 20 | Lungs (6-25%), spleen | No imaging data | 0.00 | No Tx | No Tx |
| 21 | Lungs (6-25%) | Yes | 0.00 | No Tx | No follow-up data |
| 22 | Lungs (26-50%), heart | Yes | 8.11 | Steroids | No Tx |
| 23 | Lungs (26-50%), extra-thoracic LN | No | 2.08 | No Tx | No Tx |
| 24 | Lungs (51-75%) | Yes | 2.51 | No Tx | Steroids |
| 25 | Lungs (51-75%) | Yes | 0.11 | Steroids | No Tx |
| 26 | Lungs (<5%) | Yes | 0.01 | No Tx | No Tx |
| 27 | Lungs (51-75%) | No | 0.20 | No Tx | No Tx |
| 28 | Lungs (<5%), heart, liver | No | 0.80 | No Tx | No Tx |
| 29 | Lungs (26-50%), heart | Yes | 31.6* | No Tx | No Tx |
| 30 | Lungs (51-75%), eyes, skin, extra-thoracic LN | Yes | 0.53 | No Tx | HD |
CNS, central nervous system; RA, rheumatoid arthritis; LN, lymph node(s).
LAN = thoracic lymphadenopathy, >1 cm in short diameter on computed tomography imaging.
Tx, treatment; Steroids, systemic corticosteroids, equivalent of at least 10 mg/day of prednisone; MTX, methotrexate; IFX, Infliximab, monoclonal antibody against tumor necrosis factor-alpha; HD, hydroxychloroquine.
The radiographic extent of disease in lungs shown in brackets.
*While this patient had a remote history of sarcoidosis, for concern of recurrent disease he had undergone lung biopsy (with findings of active sarcoid inflammation) at the time of blood sample collection for this study and at time of imaging to assess for LAN.